Tag: Drug Prices

Pricing Lessons from the Pharmaceutical Industry | Strategic Pricing Solutions

Pricing Lessons from the Pharmaceutical Industry | Strategic Pricing Solutions

Over the past several months, pricing strategies and practices of the pharmaceutical industry have been a subject of discussion, many times for the wrong reasons.  In particular, Valeant has come under extreme criticism for raising the prices of its drugs.  Another company, Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750.00, an increase […]

Paper: Toward Value-Based Pricing to Boost Cancer Research and Innovation | Cancer Research

Paper: Toward Value-Based Pricing to Boost Cancer Research and Innovation | Cancer Research

Abstract The high market price of new anticancer agents has stimulated debate about the long-term sustainability of healthcare systems and whether these new agents can continue to be supported by public healthcare or by private insurers. In addition, some drugs have been approved with limited clinical benefit, raising concerns about setting a minimum requirement for […]

Blog: Pricing Strategies that Last | Strategic Pricing Solutions

Blog: Pricing Strategies that Last | Strategic Pricing Solutions

I have written a number of blog posts about pricing strategies and business strategy in general.  Setting strategy is fundamentally about making choices regarding where you compete and how you win.  A very important part of making those choices is understanding how those choices affect other market constituents over a longer term.  More specifically, considering […]

Blog: Don’t Make Your Customers Angry | Strategic Pricing Solutions

Blog: Don’t Make Your Customers Angry | Strategic Pricing Solutions

Earlier this month Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750.00, an increase of more than 5000%.  There were immediate outcries of price gouging from customers who take the anti-malarial and HIV drug, insurers, doctors and politicians.   In the wake of the backlash, Turing reversed course last week and returned the drug […]

Blog: Pricing to Value – Gilead Shows the Way | Strategic Pricing Solutions

Blog: Pricing to Value – Gilead Shows the Way | Strategic Pricing Solutions

In late 2013, Gilead Sciences released Sovaldi, a drug that can cure Hepatitis C in 90 days when used in combination with other anti-viral drugs.  The initial price was more than $1,000 per day, and the total cost of treatment could exceed $80,000.  In spite of a 90% cure rate for a disease that previously […]

Report: Trends and Innovations in Drug Pricing | FirstWord

Report: Trends and Innovations in Drug Pricing | FirstWord

FirstWord’s Trends and Innovations in Drug Pricing report dissects international trends and examines how long-standing dynamics in competitive pricing and access will strengthen the payer position in demanding discounts in return for guaranteed patient access. Up-to-the-minute and based on the most current research and expert interviews, Trends and Innovations in Drug Pricing is an open […]